Literature DB >> 31183008

Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report.

Alexandra Alexopoulou1, Iliana Mani2, Dina G Tiniakos3, Flora Kontopidou2, Ioanna Tsironi2, Marina Noutsou2, Helen Pantelidaki2, Spyros P Dourakis2.   

Abstract

BACKGROUND: Idiopathic non-cirrhotic portal hypertension (INCPH) is mainly associated with thrombophilia in Western countries. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias. Portal and hepatic venous thrombosis were reported in PNH. A rare case of INCPH complicating PNH is described. CASE
SUMMARY: A 63-year old woman with a 2-year past medical history of PNH without treatment was admitted because of jaundice and refractory ascites requiring large volume paracentesis. Liver histology revealed portal venopathy with portal fibrosis and sclerosis, nodular regenerative hyperplasia, parenchymal ischemic changes, and focal sinusoidal and perivenular fibrosis without bridging fibrosis or cirrhosis, all indicative of INCPH. The flow cytometry confirmed PNH diagnosis and eculizumab treatment was initiated. Her condition was improved gradually, bilirubin was normalized 6 months following initiation of eculizumab, and 1 year later diuretics were stopped.
CONCLUSION: Eculizumab improved intravascular hemolysis and reversed clinical manifestations of INCPH in a patient with paroxysmal nocturnal hemoglobinuria.

Entities:  

Keywords:  Case report; Eculizumab; Idiopathic non-cirrhotic portal hypertension; Paroxysmal nocturnal hemoglobinuria

Year:  2019        PMID: 31183008      PMCID: PMC6547289          DOI: 10.4254/wjh.v11.i5.483

Source DB:  PubMed          Journal:  World J Hepatol


  29 in total

1.  Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview.

Authors:  P D Ziakas; L S Poulou; G I Rokas; D Bartzoudis; M Voulgarelis
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

Review 2.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

Authors:  Russell P Rother; Leonard Bell; Peter Hillmen; Mark T Gladwin
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

3.  Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome.

Authors:  Ivana Maida; Pilar Garcia-Gasco; Giovanni Sotgiu; María José Rios; María Eugenia Vispo; Luz Martin-Carbonero; Pablo Barreiro; María Stella Mura; Sergio Babudieri; Sonia Albertos; Javier Garcia-Samaniego; Vincent Soriano
Journal:  Antivir Ther       Date:  2008

4.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Neal S Young; Jörg Schubert; Robert A Brodsky; Gerard Socié; Petra Muus; Alexander Röth; Jeffrey Szer; Modupe O Elebute; Ryotaro Nakamura; Paul Browne; Antonio M Risitano; Anita Hill; Hubert Schrezenmeier; Chieh-Lin Fu; Jaroslaw Maciejewski; Scott A Rollins; Christopher F Mojcik; Russell P Rother; Lucio Luzzatto
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

5.  Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver.

Authors:  P S Kamath; H A Carpenter; R V Lloyd; M A McKusick; J L Steers; D M Nagorney; V M Miller
Journal:  Liver Transpl       Date:  2000-09       Impact factor: 5.799

6.  Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anticardiolipin antibody.

Authors:  A Austin; E Campbell; P Lane; E Elias
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

7.  Vascular involvement of the liver in Turner's syndrome.

Authors:  Dominique Roulot; Claude Degott; Olivier Chazouillères; Frédéric Oberti; Paul Calès; Nicolas Carbonell; Said Benferhat; Solange Bresson-Hadni; Dominique Valla
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

8.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.

Authors:  S Hillaire; E Bonte; M-H Denninger; N Casadevall; J-F Cadranel; D Lebrec; D Valla; C Degott
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

9.  Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection.

Authors:  Sophia Saifee; Dean Joelson; James Braude; Roshan Shrestha; Mark Johnson; Marty Sellers; Michael R Galambos; Raymond A Rubin
Journal:  Clin Gastroenterol Hepatol       Date:  2008-07-17       Impact factor: 11.382

10.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.